Introduction
The mammalian cytochrome P450 enzymes catalyze the metabolism of a wide variety of endogenous and exogenous substrates including clinically used drugs, chemical carcinogens, steroids and environmental pollutants. For decades, the P450 2B enzymes have been the primary models for investigating structure-function relationships of mammalian P450s (Zhao and Halpert, 2007) . In the past five years, the crystal structures of ligand-free, 4-(4-chlorophenyl)imidazole-bound, and bifonazole-bound rabbit cytochrome P450 2B4 (CYP2B4) have revealed that conformational changes in several regions of CYP2B4 can dramatically reshape the active site of the enzyme to fit the size and shape of the bound ligand (Scott et al., 2003; Scott et al., 2004; Zhao et al., 2006) . By combining the results of studies using mechanism-based inactivators, mutagenesis studies, homology modeling and substrate docking studies, the role of residues in B' region, F-helix, I-helix, and the K-helix of rat cytochrome P450 2B1 (CYP2B1) has been characterized (He et al., 1995; Lin et al., 2004 , Honma et al., 2005 , Kent et al., 2006 Lin et al., 2009 ). Phencyclidine and 17α-ethynylestradiol are mechanism-based inactivators of CYP2B6 and covalent modification of the apoprotein is believed to contribute to the mechanism of inactivation in both CYP2B1 and human cytochrome 2B6 (CYP2B6) (Jushchyshyn et al., 2003; Kent et al., 2006) . By using electrospray ionization-liquid chromatography-mass spectrometry (ESI-LC-MS) analysis, our laboratory has identified that the CYP2B1 apoprotein was covalently modified by phencyclidine and 17α-ethynylestrdiol, but the demonstration of protein adduct formation of these two inactivators with CYP2B6 has not been successful. The difficulty may be due to poor This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on September 19, 2011 as DOI: 10.1124 at ASPET Journals on April 1, 2017 dmd.aspetjournals.org Downloaded from ionization of CYP2B6 with LC-MS or to the low efficiency of these mechanism-based inactivators in labeling the protein. Recently, a potent mechanism-based inactivator, 4-tert-butylphenylacetylene (BPA), has been characterized for the inactivation of CYP2B1 and CYP2B4. We have had success in analyzing the BPA-inactivated apoprotein by LC-MS analysis (Lin et al., 2009; Zhang et al., 2009; Lin et al., 2010) . Here, we have used BPA as a probe to test whether it can also act a mechanism-based inactivator of CYP2B6 and, most importantly, whether we can identify the adducted apoprotein and the residue that is covalently modified by BPA using LC-MS/MS analysis.
A variety of widely used drugs including bupropion, efavirenz, methadone, ifosfamide, and cyclophosphamide are preferentially metabolized or stereoselectively metabolized by CYP2B6 (Faucette et al., 2000; Huang et al., 2000; Ward et al., 2003; Gerber et al., 2004) . Moreover, CYP2B6 is expressed in human liver, brain, kidney and lung and exhibits significant genetic polymorphisms (Gervot et al., 1999; Lang et al., 2001 ). In the past few years, because of the growing list of substrates and the potential pharmacological/clinical significance of CYP2B6, the interest in research on CYP2B6 has increased significantly (Turpeinen et al., 2006; Wang and Tompkins 2008) .
By using CYP2B6 and reductase in the reconstituted system, we report here the following: (1) the kinetic values for inactivation were determined using 7-ethoxy-4-fluoromethylcoumarin (EFC) O-deethylation as the measure of catalytic activity; (2) the mechanism of inactivation due to heme loss and covalent modification of the apoprotein were characterized by high pressure liquid chromatography (HPLC) and ESI-LC-MS, respectively; (3) the formation of BPA-glutathione conjugates was determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS); and (4) after digesting the This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on September 19, 2011 as DOI: 10.1124 at ASPET Journals on April 1, 2017 dmd.aspetjournals.org Downloaded from BPA-adducted apoprotein by trypsin, the amino acid residue that was covalently modified by BPA was analyzed by LC-MS/MS. LC-MS/MS analysis of trysin digested CYP2B6 followed by a SEQUEST search suggested that Lys274 and Thr302 were the amino acids adducted by BPA leading to inactivation. False positive results can be observed in large scale of SEQUEST data searches and, in addition, not all the covalent modification of an apoprotein is necessarily involved in mechanism-based inactivation. Thus, mutagenesis studies of Lys274 and Thr302 to Val were conducted to conclusively identify the residue whose modification was responsible for the inactivation.
To test the experimental results, BPA was docked into the active site of the crystal structure of a CYP2B6 genetic variant (Gay et al., 2010) . The active site residues within 4 Å of the reversibly bound BPA and the distance between the heme iron and the two adducted residues suggested by the SEQUEST search were examined. The docking studies are in agreement with the mutagenesis results which have revealed that Thr302, not Lys274, is the critical residue modified by BPA and which contributes to the mechanism-based inactivation. To our knowledge, this is the first time that the highly conserved Thr302 residue in CYP2B6 has been identified and further confirmed by mutagenesis to be covalently modified by a mechanism-based inactivator. In addition, the functional role of Thr302 in CYP2B6 in catalysis has not previously been characterized. This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on September 19, 2011 as DOI: 10.1124 at ASPET Journals on April 1, 2017 dmd.aspetjournals.org
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Materials and Methods
Chemicals. NADPH, GSH, catalase, and BPA were purchased from Sigma-Aldrich (St.
Louis, MO). 7-Ethoxy-4-(trifluoromethyl)coumarin (EFC) was from Invitrogen Corp.
(Carlsbad, CA). All other chemicals and solvents were of the highest purity available from commercial sources.
Site-directed Mutagenesis. The human CYP2B6 plasmid was used as a template to construct two mutant proteins at positions Lys274 and Thr302. The mutations were carried out using an in vitro QUICKCHANGE site-directed mutagenesis kit (Stratagene, La Jolla, CA). The primer 5'-CCTACCTGCTCCACATGGAAGTAGAGAAATCCAA-CGCACAC-3' was used for the Lys274 to Val conversion (K274V mutant). The primer 5'-GCTGGCAC-TGAGGTCACCAGCACCACTC-3' was used for the Thr302 to Val conversion (T302V mutant). The mutations were confirmed by DNA sequencing carried out at the University of Michigan Biomedical Core Facility (Ann Arbor, MI).
Enzyme Assays and Inactivation of the P450s. CYP2B6, the two CYP2B6 variants and reductase were expressed in Escherichia coli and purified according to previous published procedures (Scott et al., 2001; Lin et al., 2005) . To assess catalytic activity, the purified CYP2B6 and reductase were reconstituted at 22ºC for 30 min as described previously (Lin et al., 2009 ). The primary reaction mixture contained 500 pmol P450, 500 pmol reductase, 2 mM GSH, 100 units of catalase, and BPA (0.3-25 μM) in 500 μl of 100 mM potassium phosphate buffer (pH 7.7). After incubation of the primary reaction This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on September 19, 2011 as DOI: 10.1124 at ASPET Journals on April 1, 2017 dmd.aspetjournals.org Downloaded from in the absence (as the control sample) or in the presence of 1 mM NADPH at 22ºC with BPA for the time indicated (0.5-3 min), a 5 μl aliquot was removed and added to 250 μl of a secondary reaction mixture containing 50 μM EFC and 200 μM NADPH for 10 min.
The formation of the 7-hydroxy-(trifluoromethyl)coumarin product was determined on a fluorescence plate reader (excitation 410 nm; emission, 510 nm) using a Wallace Victor II 1420-042 multilabel counter (PerkinElmer, Shelton, CT). The calculations of the kinetic values for mechanism-based inactivation were performed as previously described (Lin et al., 2005) .
Determination of the Partition Ratio. BPA at concentrations ranging from 0.3 to 100 µM was added to the primary reaction mixture containing 1 μM CYP2B6. The reactions were initiated by the addition of 1 mM NADPH and incubated at 22°C for 20 min in order to allow the inactivation to go to completion (Silverman, 1996) . Aliquots were removed and assayed for residual EFC deethylation activity as described above.
HPLC Analysis of the Heme. An HPLC system with a Waters 600E system controller was used to investigate the loss of native heme and the formation of heme adducts.
Aliquots containing 100 pmol of control (-NADPH) and inactivated (+NADPH) P450, incubated with 10 μM BPA for 10 min as described above for the inactivation were then analyzed using a C4 reverse-phase column (5 µm, 4.6 x 250 mm, 300 Å; Phenomenex, Torrance, CA). The solvent system consisted of solvent A (0.1% TFA in water) and solvent B (0.05% TFA in acetonitrile). The column was eluted with a linear gradient from 30% to 80% B over 30 min at a flow rate of 1 ml/min and the column eluent was This article has not been copyedited and formatted. The final version may differ from this version. Technologies, Santa Clara, CA) equilibrated with 40% acetonitrile and 0.1% TFA at flow rate 0.3 ml/min. After 5 min, the column effluent was directed into the mass analyzer of a LCQ mass spectrometer (Thermo Fisher Scientific, San Jose, CA) as described previously (Kent et al., 2006) . The acetonitrile concentration was increased linearly to 90% over the next 25 min in order to separate the components of the reconstitution mixture and the mass spectra were recorded. The spectra corresponding to the protein envelopes for the P450s were deconvoluted to give the masses associated with each protein envelope using the Bioworks software package (Thermo Fisher Scientific). The ESI source conditions were: sheath gas set at 90 arbitrary units, the auxiliary gas was set at 30 arbitrary units, the spray voltage was 4.2 kV, and the capillary temperature was 230°C.
LC-MS/MS Analysis of GSH Conjugates.
The control and inactivated samples of CYP2B6 were prepared as described above. After the 10 min reaction, samples containing 1 nmol each of P450 were acidified with 60 µl of 10% TFA and then applied to a 1-ml AccuBond ODS-C18 solid phase extraction cartridge (Agilent Technologies, Palo Alto, CA). The cartridges were previously washed with 2 ml of methanol followed This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on September 19, 2011 as DOI: 10.1124 at ASPET Journals on April 1, 2017 dmd.aspetjournals.org Downloaded from by 2 ml of water. After the samples were loaded, the cartridges were washed with 2 ml of water and then eluted with 2 ml of methanol followed by 0.3 ml of acetonitrile. The eluted samples were dried under N 2 gas and re-suspended in 80 µl of a 1:1 mixture of solvent A (0.1% acetic acid in H 2 O) and solvent B (0.1% acetic acid in acetonitrile). The samples were analyzed on a C18 reverse-phase column (Luna, 3 µm, 4.6 x 100 mm, Phenomenex, Torrance, CA) using a gradient of 20 to 30% B over 5 min followed by a gradient to 40% B over 15 min and then increasing linearly to 90% B over 15 min at a flow rate of 0.3 ml/min. The column effluent was directed into the ESI source of a LCQ mass spectrometer (Thermo Fisher Scientific). The ESI conditions were: sheath gas flow rate, 90 arbitrary units; auxiliary gas, 30 arbitrary units; spray voltage, 4.5 kV; capillary temperature, 170°C; capillary voltage, 30 V; and tube lens offset, 25 V. Data were acquired in positive ion mode using Xcalibur software (Thermo Fisher Scientific) with one full scan followed by two data-dependent scans of the most intense and the second most intense ions.
LC-MS/MS
Analysis of the BPA-modified Peptide. BPA-inactivated CYP2B6 (500 pmol) was digested with 2 μg trypsin in 100 μl of 50 mM ammonium bicarbonate buffer (pH 8.0) at 22 ºC for 18 h as previously described (Lin et al., 2010) . The digested peptides were centrifuged at 16,000 x g and the clear supernatant was subjected to analysis by mass spectrometry using a C18 reversed phase column (Jupiter, 5 μm, 2.0 x 100 mm, Phenomenex, Torrance, CA). The initial gradient was 10 to 25% for 5 min followed by a gradient to 65% over 35 min and then increasing linearly to 95% over 10 min at a flow rate of 0.3 ml/min on a Schimadzu LC-10AD system (Kyoto, Japan). The There was a ~20% decrease in native heme of the inactivated CYP2B6 with the formation of a small amount of heme adduct that eluted at ~30 min (Fig. 3A) . Using a diode-array detector coupled to the HPLC, the wavelengths for the maximal absorbances of the native heme and heme adduct are 398 nm and 403 nm, respectively (Fig. 3B) . whether the oxygen has been added to the internal or terminal carbon cannot be ascertained from the MS/MS spectrum. Ortiz de Montellano and coworkers have previously reported that if the oxygen atom is added to the internal carbon, the heme will be alkylated and if the oxygen is added to the terminal carbon, the protein will be modified (Ortiz de Montellano and Komives, 1985; Chan et al., 1993) . The MS/MS spectrum shown in Fig. 5C for the GSH adduct formed by CYP2B6 is similar to that of the GSH conjugate formed by CYP2B1 (Lin et al., 2009 ). Since a protein adduct was the major contributor to the inactivation of CYP2B1, the structure proposed for the GSH conjugate has the oxygen inserted into the terminal carbon of the acetylene as shown in the right panel of Fig. 5C . Recently, the BPA-adducted CYP2B4 crystal structure has shown that the ligation of nucleophilic residue points toward terminal carbon of BPA triple bond (Gay et al., 2011) . The mass increase of 174 Da for the BPA-GSH conjugate is equivalent to the mass of BPA plus one oxygen and is identical to the mass increase of the apoprotein adduct in the inactivated P450, indicating that the same reactive species that is trapped to form the GSH conjugate may also be reacting with the P450 apoprotein.
Characterization of the
Unlike our findings with CYP2B1, a small heme adduct was found with CYP2B6.
Therefore, the MS/MS spectrum of GSH conjugate shown in Mutagenesis studies of Lys274 and Thr302. Since LC-MS/MS analysis indicated that two residues had been modified by BPA, but only one molecule of BPA was adducted per molecule of CYP2B6 apoprotein, the K274V mutant and the T302V mutant were constructed in order to elucidate the primary residue responsible for the mechanismbased inactivation. The EFC deethylation activity remaining after incubation of the wild type (WT) and the two variant proteins with 5 μM and 20 μM BPA for 5 min and 10 min was compared. As shown in Fig. 8 , both the WT enzyme and K274V mutant were inactivated by BPA to very similar extents, but the T302V mutant was almost completely resistant to inactivation by BPA. These results strongly suggest that the site that is covalently modified by reaction with BPA and which is responsible for the mechanismbased inactivation is the Thr302, and not Lys274.
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Discussion
The inactivation of CYP2B6 by BPA is concentration-and time-dependent. The inactivation requires the presence of NADPH. The apparent K I is 2.8 μM, the k inact is 0.7 min -1 , the t 1/2 is 1 min, and the partition ratio is ~5. These data indicate that BPA is a potent mechanism-based inactivator of CYP2B6. Following incubation of CYP2B6 with 10 μM BPA for 10 min, the loss of catalytic activity is 80%, but native heme loss is ~20%. Unlike CYP2B1 and CYP2B4, formation of a small amount of heme adduct was observed with CYP2B6 (Lin et al., 2009; Zhang et al., 2009 Based solely on the LC-MS/MS results, it is impossible to determine whether the covalent modification of Lys274 or Thr302 or both may be responsible for the inactivation. Therefore, K274V and T302V mutants of CYP2B6 were constructed and purified and used in the reconstituted system to characterize the possible roles of these residues in the inactivation by BPA. As shown in Fig. 8 eliminated in the T302V mutant. Using the same conditions as described in Fig. 4 , LC-MS analysis of the mutant proteins following incubation with BPA and NADPH revealed that a protein adduct with a mass increase of ~174 Da was observed for the K274V mutant which exhibited mechanism-based inactivation characteristic of WT 2B6, but no apoprotein adduct was observed for the T302V mutant which was not inactivated by BPA. Our mutagenesis studies showing inactivation of the catalytic activity and apoprotein adduct formation further emphasize the possibility of obtaining false positive results in SEQUEST data searches.
To better understand the experimental results, BPA was docked into the active site of the crystal structure of CYP2B6 (Gay et al., 2010) . A role for Thr302 in the mechanism-based inactivation of CYP2B4 by 2-ethynylnaphthalene has been characterized by mutagenesis studies (Roberts et al., 1996) .
The inactivation may possibly be through steric hindrance of optimal binding of the substrate, hydrophobic disruption of a proton relay pathway, or restriction of structural changes required for interaction with redutase. Recently, substrate binding studies, steady-state activity measurements, and stopped-flow experiments have suggested that BPA inactivates the catalytic activity of CYP2B4 by causing steric hindrance, which prevents the required binding of substrate to the active site of the enzyme in the proper orientation (Zhang et al., 2009) . In this study, Thr302 was identified as the site covalently modified by BPA contributing to the mechanism-based inactivation in CYP2B6. The
This article has not been copyedited and formatted. The final version may differ from this version. of the CYP2B6 protein was adducted by BPA (Fig. 4) , ~20% of the catalytic activity still remained ( Fig. 2 and Fig. 8 ). The determination of the crystal structure of BPA-bound CYP2B4 demonstrating the existence of both open and closed conformations could explain the partial catalytic activity observed here even though all of the protein is modified (Gay et al., 2011) . Docking experiments using the open structure show that BPA is able to rotate upward to give substrates some access the heme. Moreover, the crystal structure of the BPA-inactivated CYP2B4 has shown the formation of an ester bond between the oxygenated BPA and the hydroxyl group of Thr302 with the oxygen inserted onto the terminal carbon of the carbon-carbon triple bond. As displayed in Fig.   9B , our docking studies on the CYP2B6 active site structure shows that Thr302 is in close contact with the acetylene moiety of BPA. Therefore, our docking model of unmetabolized BPA reversibly bound to CYP2B6 is in good agreement with the BPAbound CYP2B4 crystal structure. In both P450s, covalent modification of the apoprotein by BPA is the predominant mechanism contributing to the inactivation. However, a noticeable difference is that a small amount of heme adduct was observed with CYP2B6, but not CYP2B4, during the inactivation by BPA. Thus far, except for BPA, the detection of both the apoprotein adduct and the identity of the covalently modified residue(s)
formed by mechanism-based inactivators such as 17α-ethnylestradiol or bergamottin with CYP2B6 has not been successful (Lin et al., 2005; Kent et al., 2006 Kent et al., , 2008 .
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